AstraZeneca trial of docetaxel, Imfinzi did not meet primary endpoint of OS

The LATIFY Phase III trial of ceralasertib in combination with Imfinzi did not meet the primary endpoint of overall survival, OS, versus standard-of-care docetaxel in patients with locally advanced or metastatic non-small cell lung cancer, NSCLC. The trial evaluated patients without actionable genomic alterations, AGAs, whose disease progressed on or after prior immunotherapy and platinum-based chemotherapy. The combination of ceralasertib and Imfinzi was generally well tolerated, and the safety profile was consistent with the known profiles of each individual medicine, with no new safety concerns identified. These data will be presented at a forthcoming medical meeting.